Nautilus Biotechnology (NAUT) Cash & Equivalents (2020 - 2026)

Nautilus Biotechnology has disclosed Cash & Equivalents across 7 years of filings, most recently posting $14.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $14.6 million, down 56.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.6 million (down 56.0% YoY), and the FY2025 annual result was $12.4 million, down 55.19% from the prior year.
• Cash & Equivalents came in at $14.6 million for Q1 2026 at Nautilus Biotechnology, up from $12.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $210.4 million in Q2 2022 to a low of $4.4 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $33.2 million (2025), against an average of $68.1 million.
• Across the five-year window, Cash & Equivalents jumped 27556.78% in 2022 and sank 94.05% in 2024, its largest moves.
• Nautilus Biotechnology's Cash & Equivalents stood at $114.5 million in 2022, then plunged by 83.06% to $19.4 million in 2023, then surged by 42.53% to $27.6 million in 2024, then tumbled by 55.19% to $12.4 million in 2025, then gained by 18.07% to $14.6 million in 2026.
• The last three Cash & Equivalents figures came in at $14.6 million (Q1 2026), $12.4 million (Q4 2025), and $23.9 million (Q3 2025), per Business Quant data.